High bifurcation of the unilateral brachial artery: an unusual variation.

BACKGROUND: It is common to observe a high bifurcation of the brachial artery, with some variations being quite rare. MATERIALS AND METHODS: During routine dissection for medical teaching purposes, a unilateral high bifurcation of the brachial artery was noted on the left side of a female cadaver. RESULTS: On the left arm, two branches of different sizes originate from the axillary artery, one on the radial side and the other on the ulnar side. These branches run down the arm, crossing each other, eventually becoming the forearm's radial and ulnar arteries. We also observed branches such as the posterior circumflex humeral artery, anterior circumflex humeral artery, and deep brachial artery. CONCLUSIONS: This case report adds to the existing body of knowledge about the variation of the brachial artery, which is of anatomical and clinical value. We report this case to highlight the unique variation in the arterial anatomy of the upper limb.

Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.

PURPOSE: The ORIENT-12 study demonstrated the promising results of sintilimab combined with gemcitabine and platinum (GP) therapy in squamous non-small-cell lung cancer (sqNSCLC) patients. However, the efficacy of sintilimab plus paclitaxel/nab-paclitaxel and platinum (TP) in sqNSCLC is not yet known. METHODS: Real-life data were retrospectively collected from patients with untreated locally advanced or metastatic sqNSCLC who were treated with sintilimab plus TP (arm A) or sintilimab plus GP (arm B) between January 2019 and January 2021. Baseline characteristics, the efficacy of sintilimab, and adverse events were analyzed. RESULTS: A total of 52 patients were included (arm A, n = 32 and arm B, n = 20). The overall response rate was 59.4% in arm A and 40.0% in arm B. The median progression-free survival was 13.9 months (95% confidence interval [CI], 6.9-21.0) in arm A and 8.5 months (95% CI, 6.9-10.2) in arm B (hazard ratio [HR], 0.61; 95% CI, 0.30 to 1.25; p = 0.18). The median overall survival was 21.3 months (95% CI, 13.4-29.3) in arm A and 13.3 months (95% CI, 9.1-17.5) in arm B (HR, 0.62; 95% CI, 0.28-1.36; p = 0.23). Adverse events of grade 3 or higher occurred in 37.5% of the patients in arm A and 55.0% of the patients in arm B. CONCLUSIONS: Sintilimab-TP may have similar clinical benefits compared with sintilimab-GP in patients with untreated advanced or metastatic sqNSCLC. These results require further validation by prospective randomized controlled studies.